A clinical trial, named OMICROHN, will be carried out to “clinically validate” a rapid blood test that will predict response to the biologic treatments adalimumab, vedolizumab and ustekinumab, the most frequently used medications for CD. The clinical trial will enroll 378 Crohn's Disease patients from the following 6 countries: Italy, Belgium, United Kingdom, Slovenia, the Netherlands, and Hungary, via 54 well-established clinical sites.
A clinical trial, named EPIPSORA, will be carried out to establish epigenetic patterns in peripheral blood that are associated with (non-)response to 3 commonly used biologic treatments adalimumab, tocilizumab and abatacept. The clinical trial will enroll approximately 200 Rheumatoid Arthritis patients from the following 3 countries: Belgium, Portugal and the Netherlands.
A clinical trial, named EPIPSORA, will be carried out to establish epigenetic patterns in peripheral blood that are associated with (non-response) to 3 commonly used biologic treatments adalimumab, ustekinumab and secukinumab. The clinical trial will enroll approximately 200 psoriasis patients from the following 3 countries: Belgium, Portugal and the Netherlands.